
Jordan Gauthier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5157510/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Advances, 2022, 6, 486-494.	5.2	25
2	Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Advances, 2022, 6, 2055-2068.	5.2	60
3	Post-CAR-T Cell Therapy (Consolidation and Relapse): Acute Lymphoblastic Leukaemia. , 2022, , 165-168.		1
4	Safety and Efficacy Comparison of Two Anakinra Dose Regimens for Refractory CRS or Neurotoxicity after CAR T-Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, S185-S186.	1.2	0
5	Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Review of Hematology, 2022, 15, 305-320.	2.2	25
6	Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood, 2022, 139, 3722-3731.	1.4	28
7	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood, 2021, 137, 323-335.	1.4	111
8	Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplantation, 2021, 56, 552-566.	2.4	113
9	Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematology,the, 2021, 8, e185-e193.	4.6	271
10	Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia. Cancer Journal (Sudbury, Mass), 2021, 27, 98-106.	2.0	2
11	CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL Journal of Clinical Oncology, 2021, 39, 7532-7532.	1.6	3
12	Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors. Bone Marrow Transplantation, 2021, 56, 2630-2636.	2.4	11
13	CMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor–modified T (CAR-T)-Cell Immunotherapy. Journal of Immunotherapy, 2021, 44, 351-354.	2.4	5
14	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1079-1109.	4.9	96
15	Long-Term Follow-up and Single-Cell Multiomics Characteristics of Infusion Products in Patients with Chronic Lymphocytic Leukemia Treated with CD19 CAR-T Cells. Blood, 2021, 138, 1749-1749.	1.4	1
16	Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell Therapy. Blood, 2021, 138, 886-886.	1.4	1
17	Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL. Blood, 2021, 138, 3872-3872.	1.4	7
18	Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy. Blood, 2021, 138, 2816-2816.	1.4	11

JORDAN GAUTHIER

#	Article	IF	CITATIONS
19	Recombinant CD19 Glycomutant Accurately and Reproducibly Detects CD19-Directed CAR-T Cells By Flow Cytometry. Blood, 2021, 138, 1724-1724.	1.4	0
20	Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2021, 138, 551-551.	1.4	15
21	Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study. Blood, 2021, 138, 529-529.	1.4	4
22	Immature platelet fraction (IPF): A reliable tool to predict peripheral thrombocytopenia. Current Research in Translational Medicine, 2020, 68, 37-42.	1.8	11
23	Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transplantation, 2020, 55, 675-680.	2.4	206
24	The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease. Current Research in Translational Medicine, 2020, 68, 71-76.	1.8	5
25	Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma. Bone Marrow Transplantation, 2020, 55, 1172-1174.	2.4	4
26	Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 957-970.	2.2	6
27	Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. Blood Advances, 2020, 4, 4869-4872.	5.2	12
28	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood, 2020, 135, 1650-1660.	1.4	222
29	Repeat Infusions of CD19 CAR-T Cells: Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival. Biology of Blood and Marrow Transplantation, 2020, 26, S267-S268.	2.0	1
30	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplantation, 2020, 55, 1525-1532.	2.4	17
31	High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics. Blood, 2020, 136, 37-38.	1.4	6
32	Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma. Blood, 2020, 136, 1-2.	1.4	2
33	Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 2020, 136, 38-39.	1.4	7
34	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood, 2019, 134, 636-640.	1.4	127
35	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia, 2019, 33, 2767-2778.	7.2	47
36	Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL. Biology of Blood and Marrow Transplantation, 2019, 25, S9-S10.	2.0	7

Jordan Gauthier

#	Article	IF	CITATIONS
37	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood, 2019, 133, 1652-1663.	1.4	277
38	Multivariate Analyses Indicate That the Cytokine Response to Lymphodepletion May be Better Associated Than Lymphodepletion Intensity with the Efficacy of CD19 CAR-T Cell Immunotherapy for Aggressive B-Cell Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, S179-S180.	2.0	1
39	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood, 2019, 133, 1876-1887.	1.4	230
40	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Advances, 2019, 3, 3062-3069.	5.2	74
41	Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC. Current Research in Translational Medicine, 2019, 67, 8-15.	1.8	4
42	Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells. Blood, 2019, 134, 201-201.	1.4	5
43	Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes. Blood, 2019, 134, 4294-4294.	1.4	3
44	Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy. Blood, 2019, 134, 3229-3229.	1.4	2
45	Bayesian Phase 1/2 trial designs and cellular immunotherapies: a practical primer. Cell & Gene Therapy Insights, 2019, 5, 1483-1494.	0.1	3
46	Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Current Research in Translational Medicine, 2018, 66, 50-52.	1.8	100
47	Association Between Low Plasma Level of Citrulline Before Allogeneic Hematopoietic Cell Transplantation and Severe Gastrointestinal Graft vs Host Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 908-917.e2.	4.4	8
48	Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplantation, 2018, 53, 400-409.	2.4	34
49	Alemtuzumab vs antiâ€thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning. European Journal of Haematology, 2018, 101, 466-474.	2.2	5
50	Successful treatment with fingolimod of graft-versus-host disease of the central nervous system. Blood Advances, 2018, 2, 10-13.	5.2	10
51	Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL. Blood, 2018, 132, 299-299.	1.4	43
52	Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma. Blood, 2018, 132, 1415-1415.	1.4	6
53	Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. Blood, 2018, 132, 1681-1681.	1.4	1
54	Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. Blood, 2018, 132, 1680-1680.	1.4	31

JORDAN GAUTHIER

#	Article	IF	CITATIONS
55	Factors impacting disease-free survival in adult B cell B-ALL patients achieving MRD-negative CR after CD19 CAR-T cells Journal of Clinical Oncology, 2018, 36, 7005-7005.	1.6	2
56	Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma Journal of Clinical Oncology, 2018, 36, 7567-7567.	1.6	5
57	Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival. Blood, 2018, 132, 281-281.	1.4	0
58	Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplantation, 2017, 52, 539-543.	2.4	30
59	Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplantation, 2017, 52, 689-696.	2.4	31
60	Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC. Bone Marrow Transplantation, 2017, 52, 878-882.	2.4	26
61	Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood, 2017, 129, 2471-2478.	1.4	200
62	Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Current Research in Translational Medicine, 2017, 65, 93-102.	1.8	85
63	Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2016, 51, 1313-1317.	2.4	28
64	Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplantation, 2016, 51, 1184-1190.	2.4	31
65	Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas. Bone Marrow Transplantation, 2016, 51, 1617-1619.	2.4	3
66	Reduced-Intensity and Non-Myeloablative Allogeneic Stem Cell Transplantation from Alternative HLA-Mismatched Donors for Hodgkin's Lymphoma: A Study By the SFGM-TC (Francophone Society of) Tj ETQq0	00.ngBT/(Dv e rlock 10 T
67	Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. Transplantation, 2015, 99, 1672-1680.	1.0	19
68	Impact of Early Post-Transplant Complications on Survival of Patients with Myelodysplastic Syndrome Undergoing Allo-SCT Following Reduced Intensity Conditioning: An SFGM-TC Study. Blood, 2015, 126, 1922-1922.	1.4	1
69	Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC. Blood, 2015, 126, 3979-3979.	1.4	30
70	Primary Failure of Platelet Recovery Is the Foremost Prognostic Factor after Allogeneic Stem Cell Transplantation Following Myeloablative Conditioning for Myelodysplastic Syndrome: A Study from the SFGM-TC. Blood, 2015, 126, 5444-5444.	1.4	0
71	Bone Marrow Involvement Detected By Multi-Parameter Flow Cytometry Predicts Poor Outcome after Autologous Stem Cell Transplantation for Peripheral T-Cell Lymphoma. Blood, 2015, 126, 1972-1972.	1.4	1
72	Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen. Bone Marrow Transplantation, 2014, 49, 1492-1497.	2.4	3

Jordan Gauthier

#	Article	IF	CITATIONS
73	Monitoring of Wilms' Tumor 1 Expression As Minimal Residual Disease in Patients with Acute Myeloid Leukemia to Predict Relapse before and after Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 1265-1265.	1.4	0
74	Plasma Citrulline Level As a Biochemical Marker to Predict and Diagnose Graft-Versus-Host Disease. Blood, 2014, 124, 3931-3931.	1.4	0
75	Contribution of IPSS-R Cytogenetics to Predict Outcome after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study from the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC). Blood, 2014, 124, 5609-5609.	1.4	0
76	Long-Term Follow-Up Of Invasive Aspergillosis In Allogeneic Stem Cell Transplantation Recipients and Leukemia Patients: Differences In Risk Factors and Outcoumes. Blood, 2013, 122, 4568-4568.	1.4	0
77	Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. Expert Review of Hematology, 2012, 5, 619-629.	2.2	15
78	The DNA Methyltransferase Inhibitor Decitabine Induces DNA Damage, Cell Cycle Arrest and Apoptosis in Multiple Myeloma. Blood, 2012, 120, 1833-1833.	1.4	3
79	Novel M-Component Based Biomarkers in Waldenström's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 164-167.	0.4	23
80	Hevylite, a Novel M-Component Based Biomarkers of Response to Therapy and Survival in Waldenstrom Macroglobulinemia. Blood, 2011, 118, 2667-2667.	1.4	2
81	The EOS® System for the Detection of Bone Lesions in Patients with Multiple Myeloma,. Blood, 2011, 118, 3921-3921.	1.4	1
82	Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. Leukemia and Lymphoma, 0, , 1-5.	1.3	0